Table 3.

Incidence of recurrent or de novo allograft NAFLD and NASH

First Author (Reference#)	Steatosis in NASH or Cryptogenic Recipients	Steatosis in Non-NASH Recipients	Progression to NASH in NASH or Cryptogenic Recipients	Median Duration of follow up (months)
Contos et al (25)	100%	25%	10%	42 ± 32
Maor-Kendler et al (26)	18%	11.6%@		12&
	38%	10.3%@	0%	45 ± 17
Tanaka et al (28)#			14%	64
Seo et al (29)	18%		9%	23
Lim et al (30)		40%	13%	44 ± 4
Dumortier et al (31)$		31.1%	10%	40 (6–189)

^@average for cholestatic, alcoholic, and HCV recipients

^#7 NASH recipients that received living donor liver transplants

^$only included non-NASH recipients without recurrent disease

^&one year protocol biopsy